8-K: Perrigo to Sell HRA Pharma Rare Diseases Business for Up to $275 Million

Perrigo Company plc has announced a binding offer from Esteve Healthcare, S.L. to acquire its HRA Pharma Rare Diseases business for up to $275 million.

Summary

• Perrigo has received a binding offer from Esteve Healthcare, S.L. to acquire its HRA Pharma Rare Diseases business.
• The total consideration is up to $275 million, consisting of $190 million in cash and up to $85 million in potential earnout payments.
• The earnout payments are contingent on the Rare Diseases business achieving certain sales milestones.
• The transaction is expected to close during the third quarter of 2024.
• The closing is subject to the HRA Works Council consultation and customary closing conditions, including regulatory approvals.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the divestiture of a non-core asset for a significant sum, but there are risks associated with the transaction and the company's future performance.

Positives

• Perrigo is divesting a non-core business unit, potentially streamlining operations.
• The company will receive a significant cash infusion of $190 million.
• There is potential for additional revenue of up to $85 million through earnout payments.
• The sale is expected to close in the near term, during the third quarter of 2024.

Negatives

• The sale is subject to regulatory approvals and the HRA Works Council consultation, which could delay or prevent the transaction.
• The earnout payments are not guaranteed and depend on the performance of the Rare Diseases business.
• The company is losing a business unit, which may impact future revenue.

Risks

• The transaction may not close if regulatory approvals are not obtained or if the HRA Works Council consultation is not successful.
• The earnout payments may not be fully realized if the Rare Diseases business does not meet the required sales milestones.
• There are risks associated with the integration of HRA Pharma and Gateway, including potential delays in sales and distribution networks.
• The company faces risks related to supply chain disruptions, economic conditions, and geopolitical events.
• There are risks associated with potential future impairment charges, customer acceptance of new products, and competition.

Future Outlook

The company expects the transaction to close in the third quarter of 2024, subject to customary closing conditions and regulatory approvals. The company also acknowledges various risks and uncertainties that could affect future performance.

Industry Context

This divestiture is part of Perrigo's strategy to focus on its core consumer self-care business. The sale of the Rare Diseases business aligns with a broader trend of pharmaceutical companies streamlining their portfolios to focus on specific therapeutic areas.

Comparison to Industry Standards

• The divestiture of a non-core business unit is a common strategy among pharmaceutical companies to optimize their portfolios, similar to actions taken by companies like Teva and Mylan in recent years.
• The valuation of the deal, with a mix of upfront cash and earnout potential, is typical for transactions of this nature in the pharmaceutical industry.
• The timeline for closing, expected in the third quarter of 2024, is consistent with the typical timeframe for similar transactions, which often require regulatory approvals and due diligence.

Stakeholder Impact

• Shareholders may view the divestiture positively due to the cash infusion and potential for future earnings.
• Employees of the HRA Pharma Rare Diseases business may experience changes due to the acquisition.
• Customers of the Rare Diseases business may see changes in product availability or support.

Next Steps

• Perrigo will proceed with the information and consultation process with the HRA Pharma Rare Diseases Works Council in France.
• Perrigo will exercise the put option granted by ESTEVE and enter into a definitive agreement.
• The company will seek regulatory approvals for the transaction.
• The transaction is expected to close during the third quarter of 2024.

Key Dates

Keywords

Perrigo, HRA Pharma, Rare Diseases, Esteve Healthcare, Acquisition, Divestiture, Merger, Sale, Earnout, Regulatory Approvals